TABLE 2.
NGS variant-derived data for three time points during LPV treatment
| Gene | Mutationa | % of reads encoding mutation atb
: |
||
|---|---|---|---|---|
| Baseline (0 mo) (405,158) | VF1 (41 mo) (250,932) | VF2 (64 mo) (604,157) | ||
| Gag | E12K | 5 | 21 | 42 |
| R76K | 0 | 0 | 2 | |
| Y79F | 0 | 0 | 2 | |
| T122A | 4.8 | 13 | 26 | |
| G123E | 5.0 | 13 | 26 | |
| V128del | 100 | 100 | 100 | |
| V370A | 5 | 0 | 1 | |
| S373T | 97 | 98 | 100 | |
| R409K | 3 | 0 | 1 | |
| S451T | 100 | 1.7 | 0 | |
| RT | K65R | 98 | 0 | 0 |
| K103N | 94 | 0 | 0 | |
| E138K | 0 | 0 | 4 | |
| Y181C | 100 | 0 | 0 | |
| M184I | 100 | 1.2 | 21 | |
| M184V | 0 | 0 | 79 | |
a
Gag mutations known to be associated with protease inhibitor exposure from prior reports and resistance-associated mutations in RT.
b
Numbers in parentheses are total numbers of reads.